JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Cytek Biosciences Inc

Gesloten

SectorGezondheidszorg

4.42 -3.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.35

Max

4.55

Belangrijke statistieken

By Trading Economics

Inkomsten

-39M

-44M

Verkoop

9.8M

62M

Winstmarge

-70.929

Werknemers

702

EBITDA

4M

-263K

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+40.13% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

12M

573M

Vorige openingsprijs

7.91

Vorige sluitingsprijs

4.42

Nieuwssentiment

By Acuity

50%

50%

177 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Cytek Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 apr 2026, 23:33 UTC

Populaire aandelen

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 apr 2026, 23:24 UTC

Winsten

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 apr 2026, 22:46 UTC

Winsten

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 apr 2026, 22:37 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 apr 2026, 22:15 UTC

Winsten
Belangrijke Nieuwsgebeurtenissen

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 apr 2026, 23:33 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 apr 2026, 23:31 UTC

Winsten

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 apr 2026, 23:31 UTC

Winsten

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 apr 2026, 23:30 UTC

Winsten

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 apr 2026, 23:30 UTC

Winsten

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 apr 2026, 23:19 UTC

Marktinformatie
Winsten

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 apr 2026, 23:09 UTC

Winsten

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 apr 2026, 23:03 UTC

Marktinformatie

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 apr 2026, 22:51 UTC

Winsten

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 apr 2026, 22:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 apr 2026, 22:48 UTC

Marktinformatie

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 apr 2026, 22:40 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 apr 2026, 22:32 UTC

Winsten

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 apr 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 apr 2026, 22:22 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 apr 2026, 22:17 UTC

Marktinformatie

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 apr 2026, 22:14 UTC

Winsten

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 apr 2026, 22:14 UTC

Winsten

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 apr 2026, 22:07 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Peer Vergelijking

Prijswijziging

Cytek Biosciences Inc Prognose

Koersdoel

By TipRanks

40.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.25 USD  40.13%

Hoogste 7.5 USD

Laagste 5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cytek Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

3.7 / 3.8Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

177 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat